34results about How to "Inhibit necrosis" patented technology

The invention discloses a spinal cord fusion agent and a preparation method and use thereof. The spinal cord fusion agent disclosed by the invention is prepared from polyethylene glycol, bone mesenchymal stem cells, Schwann cells, glial cell lined derived neurotrophic factor (GDNF), salvianolic acid and nano graphene. Studies show that the use of the spinal cord fusion agent of the invention enables rapid reconnection of divided white matter fiber tracts and gray matter staple fibers to reconstitute spinal integrity and electrical conduction and is capable of recovering motion and sensory functions below the lesion level in a short period of time, thereby effectively reducing the incidence of paraplegia and complications thereof, and no relevant products exist at home and abroad. The spinal cord fusion agent disclosed by the invention can have a wide application prospect clinically.

The invention belongs to the field of synthetic drugs, and relates to an application of geniposide in alleviating side effects of glucocorticoid, and an application of compounds represented by the formula I or pharmaceutically acceptable salts, esters, or prodrugs in preparation of drugs for alleviating side effects of glucocorticoid. The molecular action mechanism of the compounds in alleviatingthe side effects of glucocorticoid drugs has important clinical significance for developing new drugs.

The present invention belongs to the field of biomedicine, and relates to a synthetic method of a glycyrrhetinic acid ester derivative, especially a preparation method of a glycyrrhetinic acid ester derivative shown as a formula I. Specifically, a raw material of R2H contacts with glycyrrhizic acid, glycyrrhizic acid salt or glycyrrhizic acid derivative to generate the glycyrrhetinic acid ester derivative shown as the formula I in the presence of a dehydrating agent of chloride or concentrated sulfuric acid.

The invention discloses a compound ketoconazole lotion for hair. The compound ketoconazole lotion comprises, by weight, 1-2% of ketoconazole, 0.02-0.03% of clobetasol propionate, 20-26.5% of surfactant, 3-7% of cosurfactant, 0.2-0.5% of conditioner, 6-10% of foaming agent, 0.05-0.15% of ethylenediamine tetraacetic acid disodium salt, 0.5-3% of antioxidant, 0.01-0.03% of pigment and the balance purified water. Accessories used in the compound ketoconazole lotion for hair include the surfactant, the cosurfactant, the conditioner, the foaming agent, the antioxidant and the ethylenediamine tetraacetic acid disodium salt serving as the antioxidant synergist, the stabilizer and the softener. A proper number of accessories are matched with the ketoconazole and the clobetasol propionate so that the characters and the performance of the compound ketoconazole lotion for hair can be stable, the antibacterial activity of the ketoconazole and the clobetasol propionate can be brought into full play, in addition, compound ketoconazole lotion does not contain silicone oil or essence, the hair quality can be well conditioned, and the hair follicles cannot be damaged.

The invention belongs to the technical field of medicines, and particularly relates to an application of BefA protein in preparing a medicament for treating type I diabetes or complications of type Idiabetes. The medicament has an oral dosage form. The oral dosage form is a tablet, powder, suspension, emulsion, capsule, granule, pill, syrup or lemonade. According to the application, oral administration of BefA protein to T1DM mice can alleviate the symptoms of hyperglycemia and weight loss; oral administration of BefA protein can significantly reduce expression of TLR-4/NF-kappaB, which is consistent with the diabetic inflammatory signal pathway, in the pancreas of T1DM mice; and BefA protein exerts a concentration-dependent inhibition of pancreatic islet cell necrosis and promotes the differentiation and proliferation of pancreatic beta cells.

The invention provides a dipeptide derivative and an application of the dipeptide derivative. Particularly, the invention provides an N-substituted 2(1H) dipeptide derivative or a pharmaceutically acceptable salt of the N-substituted 2(1H) dipeptide derivative and a pharmaceutical composition containing the compound. The compound is capable of effectively treating various hepatic failures such as acute hepatic failure and chronic-on-acute hepatic failure.

The invention provides a dipeptide derivative for improving liver function, and its application, specifically an N-substituted 2(1H) dipeptide derivative and its pharmaceutically acceptable salt, and pharmaceutical composition containing the compound. The compound can effectively improve liver function, to lower alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or total bilirubin (Tbil). The compound can greatly improve survival rate of liver failure patient.

The invention relates to an application of berberine in preparation of a drug for treating viral myocarditis diseases caused by coxsackie virus B3. By means of the drug for treating the viral myocarditis diseases caused by the coxsackie virus B3, an effect of anti-CVB3 is achieved and an effect of inhibiting the expression of a proinflammatory factor and a chemotactic factor is significant, so that the berberine can be used for preparing the drug for treating the viral myocarditis diseases. The drug is less in side effects, is high in curative effects and is excellent in application prospect since a drug in the prior art is not satisfied in clinical treatment effects of the treatment, especially of the treatment in the later period of infection, of the viral myocarditis diseases caused by the coxsackie virus B3 (CVB3).

The invention belongs to the field of drug preparation and application, and particularly relates to application of a ribosome S6 kinase inhibitor SL0101 in the preparation of a drug for treating cardiovascular diseases. The invention aims at providing the drug for treating the cardiovascular diseases, wherein the drug contains a substance for performing treatment by taking an orphan nuclear receptor Nr4a3 as a drug target. Preferably, the effective component of the substance comprises the ribosome S6 kinase inhibitor SL0101. The application of the orphan nuclear receptor Nr4a3 as a target in the preparation of a drug for screening the cardiovascular diseases provides a very wide prospect and important significance for drug application of the ribosome S6 kinase inhibitor SL0101.

The invention relates to the technical field of medical preparations for treating scalds, empyrosis and other diseases, in particular to an ointment for treating scalds and a preparation method thereof. The ointment is prepared from, by mass, 40-60 parts of oven earth, 5-15 parts of safflowers, 5-15 parts of peach kernels, 5-15 parts of frankincense boswellia carterii, 5-15 parts of myrrh, 3-8 parts of coptis chinensis, 15-25 parts of radix arnebiae, 5-15 parts of Crinis carbonisatus, 3-8 parts of borneol, 30 parts of antelope's horn and 400-600 parts of sesame oil. The ointment can diminish inflammation, relieve pain, activate collaterals and promote tissue regeneration, is suitable for first-degree and second-degree burn, chemical burns, chronic skin fester, bedsores and other severe and lingering wounds, and is good in treatment effect, and scars are not obvious after wounds are cured.

The invention discloses a combination drug for treating acute viral hepatitis. The combination drug comprises the following active ingredients in parts by weight: 0.01-0.02 part of adefovir, 15-20 parts of rheum officinale, 15-20 parts of liquorice, 15-20 parts of fructus forsythia, 15-20 parts of white atractylodes rhizome, 15-20 parts of herba lysimachiae, 15-20 parts of sculellaria barbata, 15-20 parts of radix curcumae, 15-20 parts of raspberry and 15-20 parts of corn stigma. The preparation method of the combination drug comprises the following steps: performing reflux extraction on the raw materials by 10 times of 80% ethanol, extracting for 2h, filtering, keeping the residues, collecting the ethanol extract, decompressing and recovering the ethanol, further condensing to get a thick paste, performing vacuum or microwave drying to obtain a dry extract; adding 8 times of water to the residues, decocting and extracting for 2 times with each time for 1.5-2h, filtering, combining the water extracts, decompressing and condensing to get the thick paste, performing vacuum or microwave drying to obtain the dry extract; and combining the extracts, smashing, adding the adefovir, adding the starch or dextrin, and mixing uniformly to obtain a tablet, a granule or a capsule, and packaging.

The invention relates to a herbicide special for a soybean field.The herbicide is prepared from, by weight, 10-90 parts of flumioxazin, 1-10 parts of wetting agent, 1-10 parts of dispersing agent and 1-88 parts of carrier.The ingredients are simple, and the herbicide has the advantages of being efficient, low in toxicity, low in residue level, high in activity, low in dosage and the like.The herbicide can be degraded easily in the environment and is safe to afterreap crops, the frequency of application is reduced, and cost is reduced.As a low-toxicity fluorine-containing pesticide, the herbicide can be absorbed by buds and blades of a plant to be transmitted in the body of the plant, so that synthesis of chlorophyll is inhibited, withering, whitening, necrosis and death of sensitive weeds can be achieved quickly, and annual broadleaved weeds and part of grassy weeds in the field of soybean, peanut and orchard are effectively controlled.

The present invention discloses a preparation method of an ointment for treating burns and scalds. The preparation method comprises the following specific material preparation steps: step one, preparing the following raw materials in ratios: 8-19.2 parts by weight of rhizoma polygoni cuspidati, 8-19.2 parts by weight of baical skullcap root, 10-10.5 parts by weight of borneol, 18-22.5 parts by weight of common bletilla tuber, 27.5-30 parts by weight of calcined gypsum, 6-10.5 parts by weight of sulfadiazine, 5.5-10.5 parts by weight of amur corktree bark and 8-16 parts by weight of vaseline; step two, respectively weighing the borneol, baical skullcap root, rhizoma polygoni cuspidati, sulfadiazine, baical skullcap root, common bletilla tuber, calcined gypsum and amur corktree bark according to the parts by weight, and respectively crushing the materials into powder for a standby application; step three, conducting a sieving treatment of the powder obtained in the step two; and step four, conducting particle size detection of the obtained superfine powder obtained in the step three through a submicron microscope. The traditional Chinese medicines are combined according to related theories of Chinese and Western medicine that lung governs skin and hair, and gallbladder governs balance, the compatibility is reasonable, and the ointment is definite in curative effect, and used fortreating the scalds to relieve pain and prevent infection, can also inhibit cell necrosis on burning surface of a patient, accelerates division of cells, and is quick in response and free of scars after healing.

The invention relates to a compound as a dipeptidyl peptidase-4 (DPP-IV) inhibitor, which can be used for treating all symptoms or diseases that get benefits by inhibiting DPP-IV activity, such as type I and II diabetes, diabetes complications and other related diseases.